NCT04682145

Adverse Event Data Collection From the EUHASS Registry on Turoctocog Alfa Pegol

• Status: Enrolling By Invitation
• Phase: —
• Study type: Observational
• Enrollment: 50 (estimated)
• Sponsor: Novo Nordisk A/S · Industry
• Sex: All
• Age: —
• Healthy volunteers: Not accepted

Summary

This non-interventional study concerns a safety data collection based on adverse event data from a third-party registry (European Haemophilia Safety Surveillance System, EUHASS) that includes information about adverse events from patients with haemophilia A treated with turoctocog alfa pegol. There is no extra burden to the patients by participating in this registry-based data collection.

Conditions

• Haemophilia A

Interventions

Type	Name	Description
DRUG	Turoctocog alfa pegol	Patients will be treated with commercially available turoctocog alfa pegol according to routine clinical practice at the discretion of the treating physician. A decision to initiate treatment with commercially available turoctocog alfa pegol has been made by the patient/Legally Acceptable Representative (LAR) and the treating physician before and independently from the decision to include the patient in the registry in scope.

Timeline

• Start date: 2020-12-09
• Primary completion: 2026-02-01
• Completion: 2026-02-01
• First posted: 2020-12-23
• Last updated: 2025-09-25

Locations

1 site across 1 country: Denmark